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Abstract
Acute and chronic pain management during pregnancy, after delivery and even during 
lactation are challenging even for experienced physicians. This chapter intends to cover 
pregnancy-induced physiological changes in relation to pain conditions. It also covers 
the most common pain disorders in pregnancy and provides a comprehensive summary 
of the pharmacological and non-pharmacological options for pain management in preg-
nancy. Additionally, pain management in context of opioid abuse will also be covered, 
as high prevalence of opioid prescription is linked to the very poor maternal and fetal 
outcomes. The possibility of maternal opioid abuse and fetal opioid withdrawal should 
be known to all physicians, given its rising trends. Multimodal protocols and opioid spar-
ing strategies are highly essential for safe pain management during pregnancy and have 
been discussed. This chapter is intended to be a fast and detailed review for residents, 
pain fellows, and physicians who seek pain control in pregnant women.
Keywords: pain management during pregnancy, pregnancy related musculoskeletal 
pain, non-pharmacological pain management, opioid crisis, opioid use disorder, 
neonatal abstinence syndrome
1. Introduction
Pain during pregnancy is not necessarily limited to labor pain and includes musculoskeletal, 
urological, neuropathic, and psychosocial pain. This can pose a diagnostic and management 
challenges, especially in terms of medication selection. If left untreated, it can lead to anxiety, 
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depression, and even physical disability. Pain can persist postpartum with severe symptoms 
in 10% of patients and can sometimes last for more than 10 years after delivery [1]. There are 
multiple barriers to effective pain management in pregnancy. In addition to the complex and 
multifactorial nature of pain, there is a worldwide misconception that acute musculoskeletal 
pain during pregnancy is a normal physiological consequence that should be coped with. 
There is also fear of undesirable pharmacological effects of pain medicines on the fetus that 
prevent patients from pursuing treatment options.
Another challenge is the ongoing opioid crisis. Progressive increase in opioid prescription 
and lack of familiarity with non-pharmacological pain management or multimodal proto-
cols have led to a sharp increase in opioid abuse, admission to rehabilitation facilities, and 
increased overall maternal and fetal morbidity and mortality [2].
2. Physiological changes in pregnancy affecting pain
Pain occurring in pregnancy could be a result of mechanical and/or biochemical changes aris-
ing from changing physiology. The average pregnant woman gains 10–18 kg of weight (an 
approximate of 20% increase from baseline), doubling the mechanical load on axial joints and 
ligaments [3, 4]. The core muscles responsible for core stabilization and balance are stressed 
as well. The gravid uterus stretches the abdominal muscles and pelvic floor muscles. There 
is an upward shift of the center of gravity leading to some compensatory hyperlordosis with 
stretching of lower back muscles, significant anterior pelvic tilt with rotation of the pelvis on 
the femur, and increased use of hip extensors and abductors. There is also more head flexion 
and drooping of the shoulders [5]. Enlarged breasts and malposition during breastfeeding 
could also lead to thoracic kyphosis.
Hormonally induced structural changes include increased ligament and joint laxity, decreased 
bone density and weaker collagen, all of which have been associated with back pain [6, 7]. The 
Relaxin hormone is secreted from the placental decidua and corpus luteum to increase the myo-
metrium relaxation and cervical softening by altering the matrix metalloproteinase and glycos-
aminoglycan compositions [8]. While the correlation of Relaxin hormone level with pain has 
been inconsistent, it can contribute to joint and ligament laxity and symphysis pubis dilation 
[7]. There is fluid gain of 2–3 l, which are locally entrapped in legs and ankles which in addition 
to global water retention contributes to joint stress [9]. This further contributes to joint stress. 
Improper joint loading can persist in the postpartum period due to continued ligament laxity 
and core muscle weakness. The net effect is low back pain (LBP) and pelvic girdle pain (PGP).
3. Non-labor chronic pain
Acute and chronic pains are very common in pregnancy, with an incidence of at least 60% for 
LBP and 20% for PGP. Chronic non-labor pain is any subjective unpleasant sensory experi-
ence, both physically and emotionally, with actual tissue damage not relating to obstetric 
origin for more than 6 months. Some authors accept a 3-month timeframe if pure central 
neuromodulation has been documented [10]. Chronic pain has been associated with poor 
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academic achievement, increased job loss, disability, anxiety, depression, sexual dysfunction 
and reduction in relationship satisfaction. These collectively contribute to a lower quality of 
life (QOL) [11]. Chronic pain guidelines classify chronic pain into pain with a specifically 
identifiable pathology (such as infection or malignancy) for which there is specific treatment 
or pain with non-specific pathology. Non-specific pain could be somatic, visceral, neuro-
pathic, psychosocial, or combined. (Table 1) summarizes the type of chronic pain in pregnant 
women.
Somatic Musculoskeletal Pelvic floor dysfunction
Spondylosis
Myofascial syndrome—fibromyalgia
Visceral Gynecologic Endometriosis (most common)
Pelvic adhesive/congestion syndrome
Infections:
 Tuberculous salpingitis—chronic PID
Malignancy:
 Gynecologic malignancy
Mechanical:
 Prolapse of pelvic contents
 Adnexal cysts—cervical stenosis
Urological Congenital: Urethral diverticulum
Malignancy: Bladder neoplasm
Infection:
 Nongynecologic—interstitial cystitis
 Recurrent UTI—urethritis
Stones: (nephrolithiasis/urolithiasis)
Gastrointestinal Inflammatory:
 Inflammatory bowel disease
 Diverticulitis—colitis—celiac sprue
Malignancy: Colon neoplasm
Functional: Irritable bowel syndrome
Constipation
Neuropathic • Herniated disk—cauda equina syndrome
• Neuralgia—nerve impingement
Psychosocial • Prior or current physical or sexual abuse
• Depression—somatization disorder
• Substance abuse
Table 1. Chronic pain conditions in pregnant women.
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3.1. Musculoskeletal pain
Musculoskeletal pain is any pain that originates from muscles, tendons, or ligaments. Back 
pain and pelvic pain are among the most common types of chronic musculoskeletal pain in 
pregnancy [5]. Other less common types are cervical, thoracic, rib, abdominal wall, and chest 
wall pain. Acute musculoskeletal pain directly after labor could be due to sacral stress frac-
ture, coccydynia (from coccygeal fracture, dislocation, or contusion), perineal tear after trau-
matic vaginal delivery, or symphysis pubis pain (from contusion or symphysis separation).
3.1.1. Lower back pain
Lower back pain (LBP) is any pain occurring between the 12th rib and the gluteal fold. LBP 
commonly occurs at lumbar spine level L4-5 and is believed to be a combination of mechani-
cal strains, muscles weakness, joint laxity, and connective tissue edema without any identifi-
able etiology on imaging studies [12]. Less common causes are myofascial pain, lumbar disc 
herniations, and true sciatica. Magnetic resonance studies did not show any difference in the 
incidence of asymptomatic disc bulge or herniation in pregnant women compared with non-
pregnant women [12].
3.1.2. Pelvic girdle pain
Pelvic girdle pain (PGP) is any pain occurring between the posterior iliac crest and glu-
teal fold down to the symphysis pubis. Also called lumbopelvic pain, it is the second most 
common pregnancy-related musculoskeletal complaint after LBP; however, it is even more 
disabling. PGP is classified into four categories: unilateral sacroiliac syndrome, bilateral sac-
roiliac syndrome, symphysiolysis (separation of the pubis), and pelvic girdle syndrome (pain 
in all three pelvic joint regions, namely the two sacroiliac joints and the pubis). The sacroiliac 
joint (SIJ) is the most common source of pelvic girdle pain in pregnancy [20], followed by 
pelvic floor muscle dysfunction, which is prevalent in 50% of pregnant women with pelvic 
pain. MRI studies have reported the pregnancy-induced SIJ changes to be SIJ-bone marrow 
edema (BME), joint fluid accumulation, capsulitis, enthesitis, and subchondral sclerosis [13].
3.1.3. Risk for musculoskeletal pain
While mechanical strain can occur routinely in pregnancy, musculoskeletal pain development 
is not universal. Risk factors include multiparity, preexisting joint disorders, obesity, and 
depression. LBP progressively increases with each trimester; however, it has a favorable post-
partum course as the pain resolves at least in 80% of patients. Unfortunately, 20% of patients 
still report pain up to 3 years after delivery. The underlying etiology, severity of the symp-
toms and degree of anatomical changes (such as exaggerated symphysis widening and pelvic 
asymmetry) determine the intrapartum and postpartum prognosis. Bone marrow distension 
and joint capsular edema usually resolve after delivery, but autoimmune-related joint condi-
tions such as multiple sclerosis and rheumatoid arthritis usually flare up in the postpartum 
period after the cessation of pregnancy-induced autoimmune modulation [14, 15].
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3.2. Management of musculoskeletal pain
3.2.1. History and physical examination
A comprehensive and structured history is the first step for pain management in any patient. 
This includes:
• Detailed nature of the pain (onset, course, duration, alleviating and aggravating factors, 
and radiation)
• Functional limitations, other persistent pain conditions
• History of other comorbidities (e.g., diabetes mellitus, autoimmune diseases)
• History of illicit drug abuse
• Social and family support, coping mechanisms
• Alarming neurological signs as urinary retention (with overflow incontinence), bladder or 
bowel incontinence, saddle anesthesia, loss of anal sphincter tone, major motor weakness 
in lower extremities, and fever
• Any suspicion of infection, fracture, or malignancy should be investigated, and tertiary 
neurosurgical referral is warranted urgently
The general examination starts with inspection of the skin, spine, and pelvic contour; palpa-
tion of surrounding muscles, SIJ, and facet joints for tenderness; and determination of gait 
pattern. In SIJ and facet joint arthropathy, there is localized tenderness over the affected joints 
with increased pain on axial rotation. Discogenic pain radiates to back of the thigh and wors-
ens with the flexion of the spine.
Special physical tests for back pain are designed to provoke reproducible pain during the 
joint action with high specificity and sensitivity. Thus, they can be relied upon for prelimi-
nary diagnosis and follow up. These include active straight leg raise (ASLR) test for LBP and 
Patrick’s Faber test for PGP, pubic symphysis palpation and modified Trendelenburg’s test 
for symphysis pubis pain, posterior pelvic pain provocation (PPPP) test for posterior pelvic 
pain, and long dorsal sacroiliac ligament (LDL) palpation for SIJ pain. Physical examination 
can be helpful in identifying symptomatic herniated disc and its alarming signs. However, it 
is not very helpful to definitely locate the anatomic source of other non-discogenic pain even 
after imaging studies [16]. In general, a single physical test is less useful than combined tests 
for clinical decision, thus combined clusters of physical examinations are recommended for 
better test reliability [17].
3.2.2. Laboratory investigations for musculoskeletal pain
There are no recommendations for routine laboratory investigations for musculoskeletal 
pain unless there is suspicion of infection or malignancy. Consider CBC, ESR, and CRP in 
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suspected malignancy, or thyroid assay if hypothyroidism is suspected, and any blood inves-
tigations according to provisional diagnosis.
3.2.3. Radiological investigations for musculoskeletal pain
There are no recommendations for routine radiological scans in acute or chronic back pain with-
out warning signs. The European guidelines for diagnosis and treatment of PGP recommends 
against routine imaging for musculoskeletal pain during pregnancy. No significant differences 
were found in short- or long-term pain outcomes or functional recovery outcomes between 
immediate imaging versus routine care in patients with LBP in the absence of warning signs 
[18]. Due to poor sensitivity in detecting the early degenerative stages of SIJ arthritis, computed 
tomography (CT) and conventional radiography are not recommended. MRI is more favorable 
as a diagnostic alternative as there is no exposure to radiation and it is more reliable in discrimi-
nating changes around joints and ligaments. MRI is recommended for LBP, PGP and SIJ pain 
only in case of traumatic injuries, tumor, ankylosing spondylitis, and alarming signs [19].
3.2.4. Treatment of musculoskeletal pain
Treatment of musculoskeletal pain should be in a structured, multimodal approach. This 
involves the combination of non-pharmacological and pharmacological options. Surgical 
intervention is only reserved for emergency situations (acute disc herniation and cauda 
equina syndrome).
Non-pharmacological modalities include physical exercise and other alternatives such as 
massage, acupuncture, relaxation techniques, and chiropractic care. Physical exercise helps 
strengthen muscles of the back, abdomen, and pelvic floor to maintain core stability and aug-
ment joint stabilization.
The first line pharmacological treatment for mild pain is a short course of analgesics such as 
acetaminophen. NSAIDs can be used for no more than 2 days at a time, and it is contraindi-
cated in the third trimester and preferably to be avoided in first trimester. Opioids should also 
be avoided throughout the pregnancy. In chronic pain studies, prolonged opioid use did not 
show any benefit in functional outcome or reduction of pain intensity [20]. Moreover, it can 
increase pain sensitivity in the long run. Most medical societies agree about the judicious use 
of opioid in chronic pain, as summarized in Table 2.
3.3. Migraine
The incidence of new-onset migraine during pregnancy is around 2–3%. However, it is 
more common for pregnant women to have a prior history of migraine. Fortunately, sever-
ity and frequency of migraine symptoms reduce by 43–86%, mostly during the first trimes-
ter. Sumatriptan is considered safe and is recommended by the European Federation of 
Neurological Societies as abortive migraine therapy [21]. It is considered non-teratogenic 
and, despite the theoretical vasoconstrictor effect, no vascular malformations were reported. 
However, it has been associated with uterine atony and peripartum hemorrhage [22]. Ergot 
derivatives are contraindicated during pregnancy and lactation due to their high teratogenic 
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risk, uterine vasoconstriction, low birth weight, preterm contractions and miscarriage, and 
even convulsions in breastfed infant [23]. Beta-blockers are the first line prophylactic option 
during lactation and are considered safe during pregnancy. Angiotensin-converting enzyme 
inhibitors are contraindicated because of their nephrotoxicity and prematurity risk [22]. 
Non-pharmacological options include relaxation techniques, acupuncture, biofeedback, and 
behavioral cognitive therapy. Acetaminophen is ideal as first add-on medication. If acet-
aminophen fails, sumatriptan or NSAIDs could be added to the regimen based on clinical 
assessment and potential risk to the fetus.
Recommendation 1:
“Strong Evidence”
Optimization of non-opioid pharmacotherapy and non-pharmacological therapy 
before trial of opioids.
Recommendation 2:
“Weak Evidence”
In persistent problematic pain despite optimized non-opioid therapy, Opioid trial can 
be started if,
1. Chronic non-cancer pain
2. No current/past substance use
3. No active psychiatric disorders
Recommendation 3:
“Strong Evidence”
In Patients with current substance use disorder, Opioid is strongly not recommended.
Substance use disorder as alcohol abuse and dependence, and narcotic abuse and 
dependence should be addressed by physician.
Recommendation 4:
“Weak Evidence”
In Patients with current active psychiatric disorder, Optimization of psychiatric 
disorder is strongly recommended before Opioid trial. as long as
1. Optimal non-opioid, non-pharmacological therapy for chronic non-cancer pain 
has been achieved.
Recommendation 5:
“Strong Evidence”
In long term opioid for non-cancer chronic pain patients should be restricted to less 
90 mg morphine equivalents daily rather than no upper limit or a higher limit on 
dosing.
Recommendation 6:
“Weak Evidence”
Starting opioid for non-cancer chronic pain patients should be restricted to less 50 mg 
morphine equivalents daily rather than no upper limit or a higher limit on dosing.
Recommendation 7:
“Weak Evidence”
Opioids rotation and tapering for current opioid users in case of
1. Persistent non-cancer pain or 2. Adverse events
“Rotation is parallel with the goal of dose reduction”
Recommendation 8:
“Weak Evidence”
Tapering opioids to the lowest effective dose with the aim to discontinuation.
Recommendation 9:
“Strong Evidence”
Multidisciplinary team (MDT) program is highly recommended for patients using 
opioids and experiencing serious adverse events.
“MDT is not limited to a primary care physician, a nurse, a pharmacist, a physical therapist, a 
chiropractor, a kinesiologist, an occupational therapist, an addiction specialist, a psychiatrist, 
and a psychologist”
Table 2. Summary of the 2017 Canadian Guidelines for Opioids for Chronic Non-Cancer Pain.
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3.4. Neuropathic pain
Causes of neuropathic pain in pregnancy include carpal tunnel syndrome, meralgia pares-
thetica, low intercostal nerve compression, and the pain of a previous cesarean section wound 
scar. Physiological water retention, obesity, and diabetes are contributory factors for neu-
ropathic pain. Pregnancy-related carpal tunnel syndrome (PRCTS) is as prevalent as 43%, 
as confirmed by nerve conduction studies [24]. It manifests as pain and numbness in the 
distribution of the median nerve with progressive worsening at night. CTS usually subsides 
by conservative treatment and night splints. Physical therapy, infiltration of local anesthetic, 
and slow-release steroids could be added. Surgical decompression is rarely required and is 
reserved only for severe cases with motor neuropathy [25]. Differential diagnosis includes 
De-Quervain tendinopathy which presents with pain, swelling, and tenderness along the 
radial aspect of the wrist. Meralgia paresthetica is mononeuropathy of the lateral femoral 
cutaneous nerve (LFCN) which presents as tingling and numbness in the anterolateral aspect 
of the thigh.
4. Summary of non-labor pain management algorithm
A structured, multimodal approach is the essence of management of NLP. It is essential to 
set realistic goals based on functional status rather than chasing a pain score of zero. The 
impact of setting realistic goals of pain management has been shown to produce more patient 
satisfaction, better psychological well-being, higher quality of life and reduced anxiety 
[26, 27]. On the other hand, a patient feeling her pain is poorly controlled leads to more dis-
ability, increased pain intensity, anxiety, and depression [28, 29].
Non-pharmacological therapies are very valuable as they augment pain relief and minimize 
the utilization of drugs. These benefits are welcomed by pregnant women who often have 
concerns about medications and their side effects. Activity modifications, physical exercise, 
and a physiotherapy program have been shown to be effective in pain reduction in com-
parison with standard care. The additive benefit of combining different approaches such as 
adding acupuncture to stabilization exercises, has been proven in different studies. Pelvic belt 
bracing has been shown to improve SIJ stability by decreasing joint laxity and sagittal rotation 
by 19% [30].
5. Summary of pharmacological management
5.1. Teratogenicity and toxicity
Agents that are toxic and cause birth defects are known as teratogens [31]. During fetal devel-
opment, teratogens impart their effect mostly during the time of organogenesis which begins 
in the third week of gestation. The severity of malformation depends on many factors, includ-
ing type of teratogenic agent, dose and duration of exposure, time period of gestation, and 
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maternal and fetal health prior to the exposure. Teratogenicity can be caused by fetal cell 
death leading to spontaneous abortion, impaired cellular functions, or placental toxicity [31].
The US Food and Drug Administration (FDA) classification for safety of medications in preg-
nancy is shown in “Table 3” [32].
5.2. Opioid medications
Codeine, hydrocodone, oxycodone, and propoxyphene are currently among the most com-
monly prescribed opioid agents in the United States [33]. Opioid medications should not be 
considered as a homogenous class of medications regarding its maternal and fetal effects, as 
some subclass are safer than the others. Evidence is still inconclusive regarding the relation-
ship of opioid with poor fetal growth, preterm birth, and birth defects as most of the studies 
were biased with a lot of confounders. The general recommendation is that opioid usage 
should be avoided or minimized during pregnancy and should never be considered as a first 
line option. Usage during early pregnancy could be associated with neural tube defects and 
heart defects, and during late pregnancy, with neonatal abstinence syndrome (NAS) and neo-
natal respiratory distress syndrome. All opioid medications are classified as Class C (uncer-
tain safety, no human studies; animal studies show an adverse effect).
Fentanyl patches seem to be safe, but there is still a risk of withdrawal. Methadone is asso-
ciated with neonatal morbidity, such as preterm birth (<32 weeks of gestation), low birth 
weight, decreased head circumference, jaundice, thrombocytosis, arrhythmia, and admission 
to the neonatal intensive care unit [34, 35]. Codeine is classified as category C by the FDA [36]. 
It is neither teratogenic nor associated with congenital malformation. However, there have 
been reports of postpartum hemorrhage if it was taken near the end of pregnancy. Moreover, 
it could be rapidly metabolized into morphine, by CYP450 enzymes leading to a significant 
risk of fetal opioid toxicity during lactation [37]. Tramadol is classified as a category C medi-
cation. It has a risk of withdrawal with high maternal dosing [32]. It is not recommended to 
discontinue it during breastfeeding as only trace amounts cross into the breast milk.
The morphine equivalent daily dosage (MEDD) is a mean of calculating the daily cumulative 
intake of any opioid-related drugs. The aim is to reduce the risk of overdose, especially in 
chronic opioid use. Evidence has shown that there is no single dosage threshold below which 
overdose risk could be avoided, but opioid dosages of <50 MEDD/day (mg/day) would likely 
reduce the risk of fatal overdose.
Category A: No fetal risk in human studies
Category B: No fetal risk in animal studies, but no human studies
Category C: Harmful fetal risk in animal studies, but no human studies
Category D: Harmful fetal risk in human studies, but use is acceptable in serious situation
Category X: Harmful fetal risk in both animal and human studies.
Table 3. FDA classification for safety of medications in pregnancy.
Pain Management for Pregnant Women in the Opioid Crisis Era
http://dx.doi.org/10.5772/intechopen.79333
81
5.3. Non-opioid analgesic medications
5.3.1. Acetaminophen (paracetamol)
Acetaminophen is widely used as an analgesic. In the USA, 65–70% of women used acet-
aminophen during pregnancy [38]. It has no known maternal adverse outcomes or fetal con-
genital defects as confirmed by analysis of registries [39]. Despite the reports about increased 
risk of attention deficit hyperactive disorder (ADHD) in children if used for over 6 weeks, the 
evidence was inconclusive according to the latest FDA warning [40].
5.3.2. Non-steroidal anti-inflammatory agents
Non-steroidal anti-inflammatory agents (NSAIDs) such as Ibuprofen, Naproxen, Diclofenac, 
and Celecoxib are very commonly prescribed for analgesia. It was reported that 18–25 and 4% 
of the USA pregnant women are exposed to over-the-counter (OTC) Ibuprofen, and Naproxen 
respectively [38]. In the third trimester, NSAIDs are linked with premature closure of the 
ductus arteriosus and development of pulmonary hypertension in a fetus. At high doses, 
NSAIDs decrease renal perfusion in fetus and lead to oligohydramnios. Despite NSAIDs 
being Category B drugs before the third trimester, it is generally recommended to be avoided 
as in the first trimester there is risk of miscarriage and in the third trimester there is a risk of 
oligohydramnios and ill effect on fetal circulation. Furthermore, NSAIDs are associated with 
a delay in onset of labor and increase in duration.
5.3.3. Aspirin
Aspirin is not commonly used to treat pain or fever in pregnancy. It is associated with neo-
natal hemorrhage, IUGR, gastroschisis and perinatal death. Similar to NSAIDs, they delay 
onset of labor and increase labor duration. An increased risk of bleeding during delivery 
has also been reported. Low-dose Aspirin (81 mg) is considered safe and is commonly given 
with heparin in conditions with recurrent miscarriage and in women with antiphospholipid 
syndrome [41].
5.4. Psychotropic medications
Psychotropic drugs are medications that affect mood, cognitive function or any other mental 
process [42]. These include antidepressants, benzodiazepines, antiepileptic agents and anti-
psychotics. Most of the safety profiles and recommendations for using these drugs are based 
on retrospective observational studies in pregnant patients with underlying psychiatric or 
mood disorders (such as bipolar or depression or anxiety) and are thus liable to bias and 
confounding. Some medications are well known to cause significant congenital malforma-
tions, such as Valproate, Carbamazepine, Lithium, and Lamotrigine. Therefore, they must be 
avoided in pregnancy. Most of other drugs are debated in their fetal outcome. In general, the 
risk-benefit ratio should be weighed, and the lowest dose should be applied.
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5.4.1. Antidepressants
Patients with chronic pain commonly experience depression. Selective serotonin receptor 
inhibitors (SSRIs) and tricyclic antidepressants (TCAs) are widely used as antidepressants and 
also as adjuvant therapy for chronic pain. SSRIs have been the most commonly studied anti-
depressants in pregnancy and include Citalopram, Escitalopram, Fluoxetine, Fluvoxamine, 
Paroxetine, and Sertraline. There is little information about other SSRIs. Majority of studies 
report that SSRIs are not teratogenic; however, some consider them as low-risk teratogens as 
due to there has been associated increase, albeit minimal, in cardiac congenital anomalies in 
the form of small ventricular defects that spontaneously close in childhood [43, 44]. The use 
of SSRIs minimally increases the risk of antepartum and postpartum hemorrhage. There has 
been no increase in the risk of spontaneous abortions, perinatal deaths, or hypertensive disor-
ders of pregnancy. Peripartum fetal exposure is not believed to be associated with postpartum 
withdrawal or toxicity symptoms in the neonate. Case reports that had reported an associa-
tion were confounded by other psychotropic medications [45]. Among SSRIs, sertraline has 
the safest profile as its low levels in blood and breast milk [46].
TCAs are believed to be generally nonteratogenic except Clomipramine as reported by most 
studies. All drugs in this class could increase the risk of spontaneous abortion, hypertensive 
disorders of pregnancy, postpartum hemorrhage and transient fetal withdrawal symptoms 
[47]. There is still limited information and less usage of antidepressants drugs other than 
SSRIs, such as Selective Serotonin Norepinephrine Reuptake Inhibitors (SNRIs) and atypical 
antidepressants like Mirtazapine and Buspirone.
5.4.2. Benzodiazepines
A majority of studies report benzodiazepines to be nonteratogenic. Even the few conflicting 
reports showed that the incidence of minor anomalies such as cleft palate is only minimally 
increased compared with the general population. Perinatal usage increases the risk of low 
birth weight, preterm labor and spontaneous abortion. Moreover, peripartum exposure is 
associated with withdrawal and toxicity symptoms [48].
5.4.3. Antiepileptic agents
Antiepileptic drugs are now commonly used in pain management, particularly for the treat-
ment of neuropathic pain such as, trigeminal neuralgia, diabetic neuropathy, post-herpetic 
neuralgia, post-stroke pain, phantom limb pain and pain after spinal cord injuries. Majority 
of studies have reported significant fetal morbidity due to in-utero exposure that including 
major anomalies like neural tube defects, congenital heart abnormalities, and urinary tract 
defects, skeletal abnormalities, cleft palate and impaired cognitive and motor development 
[49, 50]. Pregabalin, which is very commonly prescribed for chronic neuropathic pain, has a 
better safety profile than other antiepileptics. However, it is still associated with a higher risk 
for malformation than in the general population [51].
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5.4.4. Antipsychotic agents
In recent times, Olanzapine, the atypical antipsychotic, has been gaining popularity in chronic 
pain management. A majority of studies report Olanzapine as nonteratogenic and not asso-
ciated with spontaneous abortions or major congenital malformations. Nevertheless, it has 
been associated with an increase in birth weight [52].
6. Non-pharmacological management
6.1. Physical therapy
Physical therapy has been one of the cornerstones of chronic pain treatment, replacing the 
original approach of rest. Activities are aimed at restoring flexibility, strength, and endur-
ance, as well as reducing the severity of chronic pain through modulation of the biochemical 
processes within the body [30, 53]. Numerous physical therapy programs exist (e.g., aero-
bic, yoga, tai chi, strength, pilates, flexibility, and range of motion), and each one differs in 
frequency, intensity, and design. Despite the high utilization of physical therapy and sev-
eral studies that have demonstrated its benefits in chronic pain, the effectiveness of physi-
cal therapy is unclear and current high-quality evidence to support such claims are lacking 
[53–56]. Absolute contraindications are myocardial infarction, ongoing unstable angina, and 
severe aortic stenosis [56]. Adverse effects of physical therapy are rare with musculoskeletal 
injury being the most common. Other potential adverse events include pain exacerbations, 
soreness, rhabdomyolysis, dehydration, hypo- and hyperthermia, and cardiac and respira-
tory events [57]. Importantly, neither the AHA nor the systemic reviews site pregnancy as 
an absolute or relative contraindication to physical therapy. Currently, the consensus is that 
the potential benefits of physical activity in pain relief, and improved quality of life outweigh 
its risks. For maximum effectiveness and minimum adverse effects, the evidence suggests 
that supervised and structured program schedules are superior to self-supervised and vary-
ing program schedules [53]. Moreover, adding a specifically tailored training to a standard 
physical exercise has less disability and more functional recovery at 2 years postpartum in 
comparison with physical exercise alone [58].
6.2. Acupuncture
Acupuncture is a technique where needles or other modalities are used to stimulate prede-
termined locations throughout the body to promote the flow of ‘Qi’ and rebalance the body’s 
energy. Although the practice originated in China thousands of years ago, the specific mecha-
nism of action has yet to be uncovered. Current theories suggest that acupuncture boosts 
the body’s intrinsic neuropeptide pathways, including endogenous opioids. However, these 
effects appear to be short term and do not explain the longer term benefits of acupuncture 
[59]. Due to the heterogeneity of acupuncture techniques, outcomes are hard to study and 
compare. A few studies have shown benefits, including several randomized controlled tri-
als which demonstrated acupuncture to be an effective alternative to pharmacologic treat-
ment [60]. However, these studies focused on labor-related pain and not chronic pain during 
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pregnancy. In addition, meta-analyses have suggested that any superiority of acupuncture 
over sham acupuncture is not clinically significant [61, 62]. The literature does not suggest any 
absolute contraindications to acupuncture, but relative contraindications are similar to other 
needling techniques used for the treatment of pain. The incidence of serious adverse risks 
is rare (estimated to be 0.05 per 10,000 treatments) and is generally associated with poorly 
trained or unlicensed acupuncturists. The two most common adverse risks reported in one 
study were needling pain (3.3%) and hematoma (3.2%). Other risks include bruising, syncope, 
exacerbation of symptoms, paresthesia, infection, retained needle, and damage to surround-
ing tissues [63]. Two studies have commented on the adverse effects of acupuncture during 
pregnancy, and both suggest that, provided the practitioner avoid locations associated with 
the cervix and uterus, acupuncture is safe for both the mother and the fetus [64]. Despite the 
lack of evidence for the efficacy of acupuncture, the overall consensus is that acupuncture’s 
benefits outweigh its risks, and that a trial of acupuncture can be considered in interested 
patients when the availability of other safe treatment options is limited.
6.3. Botulinum toxin
Botulinum toxin has been reported safe during the first trimester of pregnancy [65]. Although 
research for the use of Botox as a treatment for several chronic pain syndromes (e.g., myo-
fascial pain, neuropathic pain) is promising, the only FDA-approved indications of Botox 
(serological types A and B) related to the treatment of chronic pain conditions are spasticity 
and chronic migraine. Evidence suggests that Botox is effective in providing pain relief for 
several months as a result of its long half-life [66]. Animal studies have shown some fetal 
damage, but the risk is uncertain in humans due to lack of sufficient evidence. Botox is clas-
sified by the FDA as a pregnancy category C drug. The current recommendation by the FDA 
is that Botox should be “administered during pregnancy only if the potential benefits justifies the 
potential risk to the fetus.” In addition, other more conservative treatments should be exhausted 
first. If Botox is considered, the risk and benefits should be acknowledged by the patient prior 
to proceeding.
7. Interventions for pain management
7.1. Radiofrequency ablation
Radiofrequency ablation (RFA) is a process of nerve destruction via radiofrequency-generated 
heat by insertion of a catheter or electrode close to the target nerve under fluoroscopic guid-
ance, confirming the correct location through sensory and motor testing, and applying a 
preset temperature for a fixed time period. This aims for neuromodulation of pain pathway 
by disruption of the transmission of nerve impulses from the pain generators to the central 
nervous system. The most common application of RFA is for the treatment of facet joint pain. 
Other applications include discogenic pain, radicular pain, and sacroiliac pain. Generally, a 
diagnostic and therapeutic block with local anesthetic with or without steroid is required to 
proceed with RFA. Current evidence suggests that RFA treatment has a modest, short-term 
benefit at best, with no long-term pain improvement, as supported by a recent meta-analysis 
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[67–69]. Contraindications to RFA are like those associated with other neuraxial procedures. 
Complications include increased pain, muscle spasms, numbness or paresthesias, infection, 
bleeding, superficial burns, damage to surrounding tissues, side effects of local anesthetics 
as well as fetal exposure to radiation. As a general rule, ultrasound and magnetic resonance 
imaging are the preferred imaging methods during pregnancy. Ionizing radiation (e.g., fluo-
roscopy) in large doses can have varying effects to the fetus via pregnancy loss, malformation, 
growth disturbances and mutagenic and carcinogenic effects depending on the stage of gesta-
tion. The most sensitive period of gestation to radiation occurs during organogenesis (weeks 
2–8) [70]. The recommended maximum dose of radiation for the duration of pregnancy varies 
by source, but has been sighted as low as 500 mrem (or 0.5 Rads). For comparison, a pregnant 
interventional radiologist can expect an average dose of 30 mrem during a 40-week pregnancy 
if wearing double lead [71]. Radiation is not an absolute contraindication to RFA in the preg-
nant patient, and if clinically indicated RFA via fluoroscopy can be considered. Benefit–risk 
ratio of RFA is an important first step and if in doubt, a radiologist could be consulted. Since 
the average exposure of radiation during a fluoroscopic-guided RFA is not well defined in the 
literature, various methods should be employed to minimize the risk of exposure to the fetus. 
Some of these techniques include shielding the abdomen and pelvic region with lead, mini-
mizing fluoroscopic exposure time, proper placement of the fluoroscope to maximize distance 
from the X-ray source, limit magnifications, narrowing of the fluoroscopic window (known 
as tight collimation) and proper gestational timing of the procedure [70]. Given the limited 
evidence of RFA, the lack of quality evidence of RFA during pregnancy, and the potential for 
radiation exposure to the fetus, RFAs should only be considered after failure of conservative 
treatments and an informed discussion with the patient.
7.2. Transcutaneous electrical nerve stimulation
Transcutaneous electrical nerve stimulation (TENS) is a technique of delivering low level of 
constant electrical impulses of variable frequencies, intensities and pulse waveforms to the 
epidermal surface with aim of inhibition of spinal cord interneurons and descending pain 
pathways [62, 72]. The indications for TENs are various, and examples include lower back 
pain and myofascial pain. Onset of pain relief takes on average 20–30 min in 75% of patients 
and 1 h in 95% of patients. The duration of pain relief varies among patients and conditions, 
but appears to be short term, decreasing over past several months of use [73]. During labor, 
TENS has demonstrated a benefit in acute pain relief, decreased analgesic use, and patient sat-
isfaction [61, 74]. In contrast, two systemic analyses and a Cochrane review have not shown 
a significant reduction in pain [62, 75]. Technical errors from electrodes placement and tim-
ing could lead to interference with fetal heart monitoring and possible premature labor. All 
can easily be corrected by proper timing, proper anatomical placement of the devices, and 
removing the TENs if necessary [61]. Overall, the benefit of TENS for the treatment of chronic 
pain during pregnancy is not well studied in the literature. The general consensus is that the 
device’s benefits outweigh its risks. TENS is easy to use and accessible over the counter. It 
provides a cost-effective, noninvasive, and potential pharmacologic sparing effect in pregnant 
patients and may be considered as an adjuvant for the safe treatment of chronic pain during 
pregnancy.
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8. Special topics in pregnancy
8.1. Opioid use disorder in pregnancy
Opioid use during pregnancy has increased worldwide in recent years. In the United States, 
the prevalence of opioid abuse or dependence among pregnant women has increased from 1.7 
per 1000 delivery admissions in 1998 to 3.9 per 1000 delivery admissions in 2011. The rate of 
unintended pregnancy has been reported as high as 86% in women with opioid use disorder, 
exposing the fetus right from conception [76]. Increase in opioid-related morbidity has been 
directly linked with the high prevalence of opioid prescription, which reaches 27–39% among 
pregnant women [77]. Opioid use disorder (OUD) is a pattern of opioid intake associated with 
significant clinical impairment and distress. OUD is diagnosed, as described in (Table 4) by 
the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5), by at least two 
criteria within a 12-month period [78].
Treatment of pregnant women with OUD has been shown to improve maternal and fetal 
outcome by decreasing the risk of relapse, maternal withdrawal symptoms, drug-seeking 
behaviors, and repeated cycles of intoxications [79, 80]. It also enhances the adherence to 
prenatal care. Opioid dependence in pregnancy is directly linked to placental insufficiency, 
fetal growth restriction, fetal death, abortions, premature delivery, preeclampsia, abruptio 
placentae, premature rupture of membranes, and postpartum hemorrhage. However, clear 
causality could not be established in the studied populations because of confounders in 
from of polydrug abuse, opioid withdrawal symptoms or coexisting maternal conditions 
[81]. Medical, nutritional, financial, psychological and socio-economical rampant in this 
patient population and should be taken into consideration when formulating a treatment 
plan.
Opioid use disorder (OUD)—DSM-5 Diagnosis by at least 2 criteria over 12 months.
• Opioids intake in larger amounts or over a longer period than was intended
• Craving, “strong desire or urge” to use opioids
• A persistent desire or unsuccessful efforts to cut down or control opioid use
• A great deal of time is spent to obtain, use or recover from the opioid
• Failure to fulfill major role obligations at work, school, or home
• Recurrent opioid use in physically hazardous situations
• Reduction in important social, or recreational activities.
• Continued opioid use despite the opioid related physical or psychological problem Continued opioid use 
despite the opioid related social or interpersonal problems
• Tolerance
• Withdrawal
Table 4. DSM-5 diagnostic criteria for OUD.
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Autonomic nervous system activation
 Fever—sweating
 Temperature dysregulation
 Increased respiratory rate
 Nasal stuffiness, sneezing
Central nervous system irritability
 High-pitched continuous crying
 Irritability—decreased sleep
 Tremors—muscle hypertonicity
 Seizures
Gastrointestinal dysfunction
 Feeding difficulties
 Vomiting—loose diarrhea
Cardiovascular dysfunction
 Tachycardia—hypertension
 Hypotension in case of collapse
Table 5. Summary of neonatal abstinence syndrome (NAS).
Methadone is still the standard treatment for the opioid dependence in many institutions 
due to its proven safety profile and established efficacy. Recently, the American College of 
Obstetrics and Gynecology (ACOG) has recommended buprenorphine as the first line ther-
apy in OUD [82]. The interest is growing for buprenorphine after retrospective reports for 
its benefit of lower rates, lesser severity of NAS, lower morphine doses used for NAS, and a 
shorter stay in NICU [83]. Buprenorphine has a ceiling effect with expected low risk for over-
dose compared with methadone. The efficacy of buprenorphine as a substitution therapy has 
been debated because it was found that the patients on buprenorphine have less compliance 
rate and more reversion to other opioid drug abuse; however, those reports were biased and 
have different patient characteristics [34]. Both buprenorphine and methadone are considered 
safe with no significant harm and have shown good outcomes in OUD treatment [35].
8.2. Neonatal abstinence syndrome
As a shadow of opioid crisis and high prevalence of maternal opioid exposure, the incidence 
of NAS has increased worldwide. In the USA, a 400% increase in the incidence of NAS were 
reported and 5.8 up to 30 per 1000 hospital births in 2012, compared with 1.2 in 2000 [84, 85]. 
In 2012, one NAS-affected infant was born every 25 min in the United States [85].
Neonatal abstinence syndrome (NAS) is a neonatal drug withdrawal syndrome that occurs 
after opioids exposure in utero. The opioid is the main culprit for the withdrawal; however, 
other substances have also been reported, including alcohol, benzodiazepines, nicotine, and 
psychiatric medications such as antidepressants or antipsychotics [86]. The source of the opi-
oid could be from clinician-approved use of prescription opioids for pain relief, or abuse of 
prescription opioids or illicit use (e.g., heroin); or medication-assisted treatment (MAT) of 
opioid use disorder.
In utero, fetal exposure to opioids during pregnancy is associated with a 60–80% risk of NAS 
[87]. However, the onset and severity are multifactorial and variable. They depend on ges-
tational age, birth weight, maternal opioid dosage, concomitant use of other psychoactive 
medications and pharmacogenomics. NAS usually manifests within 2–3 days after birth with 
clinical signs of withdrawal as summarized in Table 5 [88].
Multiple brain volumetric studies have reported a small volume of cortex, deep midbrain, brain-
stem, and thin cerebellar cortex in infants with in utero polydrug exposure including opiates [86]. 
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Long-term neurodevelopmental sequelae such as attention deficit disorders (ADD) and dis-
ruptive behavior have been reported in NAS. Therefore, long-term psychiatric follow-up is 
warranted [89]. Inpatient monitoring for 4–7 days for neonates with known in utero exposure 
to opioids is recommended by the American Association of Pediatrics (AAP) [88].
Non-pharmacological management is the initial approach for NAS. It entails keeping the 
neonate in calm, soothing environment with minimal stimulation, repeated maternal contact, 
and frequent hypercaloric meals [90]. Pharmacologic treatment is usually needed. This consti-
tutes oral morphine as the first line agent and either clonidine or phenobarbital as the second 
line agent [85]. Once withdrawal symptoms are stable for 48 h, pharmacological weaning 
can be started. Breastfeeding is recommended in general even for mothers on methadone or 
buprenorphine treatment, as long as no other contraindications are present (e.g., HIV, illicit 
drug use) [82].
9. Recommendations summary
Chronic pain management in pregnancy is challenging. A multidisciplinary team approach 
and multimodal pain protocols are highly recommended. Optimum management includes 
a detailed review of the patient’s comorbidities and considerations for behavioral and other 
socioeconomic factors that could affect chronic pain conditions. The safest approach is by 
following a goal-directed strategy that minimizes or optimizes opioid usage. Opioid sparing 
strategies include early alternative pain therapies such as exercise, physical therapy, behav-
ioral changes, and non-opioid analgesics. Lifestyle and behavioral changes start with open, 
effective, and compassionate communication with the patient. The initial and follow-up visits 
should include patient education on different pharmacological options and alternative non-
pharmacological modalities. Patients should be encouraged to take an active role in their own 
treatment plan. Acetaminophen is usually the first line drug for mild to moderate pain in any 
stage of pregnancy. Although ibuprofen is the non-steroidal anti-inflammatory drug (NSAID) 
of choice, it is contraindicated after 28 weeks of gestation as it could cause premature closure 
of the ductus arteriosus and impair fetal kidney function. Only in severe acute musculoskel-
etal pain, opioids should be used. Caution should be taken as peripartum administration 
is associated with neonatal respiratory depression. Additionally, a long-term therapy, par-
ticularly in late pregnancy, is associated with adaptation disorders and neonatal withdrawal 
symptoms. Once the opioids are indicated in a reproductive age woman, the benefits and risks 
of opioid use should be discussed. However, concerns about NAS or opioid abuse should 
not be a barrier for optimal pain management in pregnancy as long as a cautious and bal-
anced approach is followed. Opioid prescriptions should be initiated with a drug monitoring 
program that could help to identify opioid use disorder or drug misuse. Concurrent opioid 
and benzodiazepines use should be avoided whenever possible. Opioid overdose is associ-
ated with high maternal and fetal mortality and morbidity. In case of overdose, substance 
abuse disorder, or higher opioid dosages (≥50 MME/day), naloxone should be prescribed. To 
avoid relapse, which is associated with very high morbidity in pregnant women with opioid 
use disorder, an opioid agonist (buprenorphine or methadone) is the recommended first line 
therapy in combination with behavioral therapy. Antiepileptic drugs are contraindicated dur-
ing pregnancy as they carry a teratogenic risk; however, well-studied antidepressants, such 
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as sertraline and amitriptyline can be used for chronic pain with the appropriate indications. 
Sumatriptan is safe to use in pregnant patients with migraine.
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